- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 64,10 | -0,80 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| CSPC PHARMA | 0,808 | +2,26 % | CSPC PHARMA (01093): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | ||
| SELLAS LIFE SCIENCES | 7,200 | +0,84 % | Sellas Life Sciences: 28,7 Mio. US-Dollar aus Optionsscheinausübung stärken Bilanz | ||
| MADRIGAL PHARMACEUTICALS | 426,00 | +0,80 % | Madrigal Pharmaceuticals-Aktie: Wird Rezdiffra zum Mega-Blockbuster? | Die Aktie von Madrigal Pharmaceuticals zählt zu den auffälligsten Gewinnern im Biotech-Sektor der vergangenen Jahre. Entscheidend für die weitere Entwicklung ist die Frage, ob sich das Unternehmen mit... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,260 | -2,38 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,100 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| METRIOPHARM | - | - | Press Release: MetrioPharm AG: Prof. Dr. med. Jürgen Braun Appointed as New Member of the Scientific Advisory Board | Press Release: MetrioPharm AG: Prof. Dr. med. Jürgen Braun Appointed as New Member of the Scientific Advisory Board
-- Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of
MetrioPharm... ► Artikel lesen | |
| OPUS GENETICS | 3,800 | +7,95 % | Opus Genetics, Inc.: Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product | Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture... ► Artikel lesen | |
| SAVARA | 4,616 | +4,41 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,100 | +3,96 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,360 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,027 | -14,29 % | Biocurious: Ahead of this year's Big Freeze, Neurizon hopes to 'do it for Daniher' | ||
| CIPHER PHARMACEUTICALS | 10,100 | 0,00 % | Cipher Pharmaceuticals GAAP EPS of $0.24 beats by $0.10, revenue of $12.51M beats by $0.31M |
Das Unternehmen LOTUS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.